[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Elsewhere the sky is the roof of the […]
Articles
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. You can see his biography, previous columns and most recent comments on his Stock Gumshoe page.] “We ran the race, the race […]
[ed. note: This article originally ran on October 6, 2015. The ad is circulating again and generating questions here at Stock Gumshoe, and it appears unchanged. The article that follows is also unchanged and has not been updated. The stock being teased by Money Morning is essentially unchanged in price from when this article was […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
Special Update on Cellceutix[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
[Ed. Note: Dr. KSS, formerly knowns as karmaswimswami on our discussion threads, is here again to talk to the Irregulars about health and medicine and biotech investing ideas. As with all of our guest contributors, he has agreed to our trading restrictions and we have not reviewed, approved or screened his stocks or ideas, and […]
[ed note: This is the latest in a series of articles from medical writer “Doc Gumshoe” (who, yes, is not actually a doctor) — it’s on the hot topic if antibiotic resistance, and we’ll likely continue to see companies touted and teased that aim to either fight resistant bacteria or clean up hospitals to slow […]
Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing […]
Comments
Achaogen Appoints Halley Gilbert to Its Board of Directors $AKAO Achaogen, Inc. a clinical-stage biopharmaceutical co...
Today I received (yet another) spiel today about how Mark Skousen's oft-touted Elite "SS-4 Income Stream" could make me ...
Glenn, I think that the devil (in this case the angels) is/are in the details. The Sec filing regarding the $ZFGN direct...
AKAO has a Cubist xSVP on Board- :-) Long. Thanks Dr. KSS! Achaogen Announces Appointment of Greg Stea to Board of ...
Like the hire for Trevena (TRVN)with her pain medicine and acute heart failure background with Merck. Trevena Appoint...
"One more thing!" -- Colombo I received this over the weekend from S & A Master Series: The four new gram-negat...
Following Fierce Biotech article published today rekindles the fire re rumors of CBST as Big Pharma merger/acquisition t...
This from CTIX this morning.Exciting times ahead.I think management is executing nicely. Cellceutix Believes Brilacid...
AKAO news Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from...
Dovetailing into JZ's mantra of buying Big Pharma, Mathew Carr from the Oxford Emerging Trends Trader (a VIP service new...
Oops, didn't dig deep enough. Trius was bought out in Sept. 2013 by Cubist Pharmaceuticals, which is trading ~$76....
This from 5/26/11: BOSTON (MarketWatch) -- Shares of Cambridge, Mass.-based Cubist Pharmaceuticals were up 6% in morning...
Cubist Pharmaceuticals, the drug is cubicin CBST ...